Dr. Hidalgo is the Theodore W. and Evelyn G. Berenson Professor of Medicine at Harvard Medical School, chief of the division of Hematology and Oncology and director of the Rosenberg Clinical Cancer Center at the Beth Israel Deaconess Medical Center.
Dr. Hidalgo previously served as assistant professor of medicine in hematology and oncology at the University of Texas Health Science Center in San Antonio in 2000. In 2001, he relocated to Johns Hopkins University to serve as director of the Gastrointestinal Oncology Program at the Sidney Kimmel Comprehensive Cancer. In 2009 he became director of the clinical research program at the Spanish National Cancer Center in Madrid and was made vice-director of translational research there in 2011.
His main focus of research has been new drug development in pancreatic cancer. His group popularized the used of Avatar mouse models for cancer research and recently contributed to the development and approval of Nab-paclitaxe for pancreatic cancer treatment.
Dr. Hidalgo trained in medicine and medical oncology at Hospital “12 de Octubre” in Madrid and at the University of Texas Health Science Center in San Antonio, and completed a fellowship in anticancer drug development at the Institute of Drug Development in San Antonio. He received his medical degree from the University of Navarra in Pamplona, Spain, and a Ph.D. from University Autonoma of Madrid .
